

INN Nomenclature Scheme For Cell Therapy Products (CTP)

*International Nonproprietary Names (INN) Programme
Technologies Standards and Norms (TSN)
Regulation of Medicines and other Health Technologies (RHT)
Essential Medicines and Health Products (EMP)
World Health Organization, Geneva*

© World Health Organization 2015
All rights reserved.

This health information product is intended for a restricted audience only. It may not be reviewed, abstracted, quoted, reproduced, transmitted, distributed, translated or adapted, in part or in whole, in any form or by any means.

The designations employed and the presentation of the material in this health information product do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

The World Health Organization does not warrant that the information contained in this health information product is complete and correct and shall not be liable for any damages incurred as a result of its use.

INN Nomenclature Scheme for Cell Therapy Products (CTP)

During the 61th INN Consultation in 2015, a USAN-INN-harmonized nomenclature scheme for cell therapy products (CTP) (shown in Table here below) was formally finalized and approved by the members of the INN Expert Group designated to deal with the selection of international nonproprietary names*.

Prefix: <i>random</i>	Infix1: manipulation/s ¹	Infix2: cell type	Suffix: -cel
to contribute to euphonious and distinctive name e.g. <i>al-</i> ; <i>bet-</i> ; <i>val-</i> ...	to specify, if appropriate, which manipulation the cells have undergone, using, when available, existing infixes for manipulation ² : e.g. -gen- : transduced (genetic modification) -fus- : fusion to a cell	to identify the primary cell type ³ using, when available, existing infixes for cell types : e.g. <i>-den-</i> dendritic cells <i>-isle-</i> islet cells <i>-mio(b)-</i> myoblasts <i>-co(n)-</i> chondrocytes <i>-fi(b)-</i> fibroblasts <i>-ker(a)-</i> keratinocytes <i>-end(o)-</i> endothelial cells <i>-ep(a)-</i> hepatocytes <i>-mestro-</i> mesenchymal stromal cells (msc) <i>-ret-</i> retinal epithelial cells <i>-ren-</i> renal tubular cells <i>-pla(c)-</i> placenta cells <i>-ur-</i> urothelial cells <i>-ova-</i> ovary cells <i>-tesi-</i> testis cells <i>-cor-</i> umbilical cord cells <i>-leu-</i> lymphocytes/monocytes/APC (white cells) ⁴ <i>-tem-</i> stem cells <i>-defitem-</i> differentiated stem cells (not filling in any existing category) <i>-tu-</i> tumor cells	to name <i>all</i> CTP, with the <i>exception</i> of : -Minimally manipulated hematopoietic elements, -combination products

* INN selected before the adoption of the present nomenclature scheme may follow different rules.

-
- 1) There may be more than one manipulation infix in the same INN.
 - 2) In the case of manipulation such as cell expansion and cell activation (with cytokines/drug, etc.), there is no need for an infix, but this kind of manipulation would be specified in the description.
 - 3) Residual, contamination cells are not named.
 - 4) The cell type infix *-leu-* will be used to describe hematopoietic cell preparations that do not fit a particular or specific cell type. Such cell preparations may be comprised of a mixture of the various blood cell elements, a subset of blood elements such as T- B- or NK-cells, or antigen presenting cells (APCs) that do not fit the definition of dendritic cells fall into this category.

Note:

Information concerning manipulations and/or modifications, and the type of the CTP (i.e. allogeneic, autologous and xenogeneic) would be specified in the description of the product.